Paul Chazot, BSc, PhD

Professor Chazot's research group focuses on the identification, characterisation and validation of novel drug targets and strategies for the treatment of the major chronic CNS pathologies. He has also developed novel prodromal neurodiagnostic biomarkers, and validated behavioural tests for both animals and humans. Prof Chazot published the first evidence proposing the clinical use of PBMT 1070nm in immuno and neurodegenerative diseases. Prof Chazot authors multiple patents, and is heading up multiple clinical trials including Alzheimer's, post-concussion syndrome, and chronic pain.